



Yellow Fever Partners Meeting on the Updated Strategy for the Elimination of Yellow fever Epidemics (EYE)

Co-organized by the World Health Organization (WHO) and the Gavi Alliance (Gavi)

12 September 2016, WHO HQ, Geneva (Salle B)

Preliminary Agenda

Purpose

Bring together partners involved in development and implementation of the updated strategy for the Elimination of Yellow fever Epidemics (EYE)

Objectives

- 1. Update partners on EYE objectives and strategic axis
- 2. Engage with partners on EYE development and implementation
- 3. Define immediate and long term steps to support the EYE strategy

Session 1: Introduction

9:00-9:05	Opening remarks, Sylvie Briand, WHO HQ & Seth Berkley, Gavi
9:05-9:15	Presentation of the objectives and expected outcome of the meeting, $Sylvie\ Briand$, $WHO\ HQ$
9:15-9:20	Participants presentation

Session 2: Background

Chair: Ibrahima-Soce Fall, WHO AFRO

9:20-9:30	Review of recent yellow fever epidemics and of the Yellow Fever Initiative, <i>Sergio Yactayo</i> , <i>WHO HQ</i>
9:30-9:40	Historic review and risk forecasting, Duane Gubler, Duke-NUS Medical School
9:40-10:00	Discussion

10:00 - 10:30 Group photo & Coffee break (Salle B)

Session 3: Resetting the 2017-2026 yellow fever strategy

Chair: Philippe Stoeckel, AMP

10:30-10:40	Objectives of the long-term strategy to Eliminate Yellow fever Epidemics (EYE): what is new, why was it needed, <i>Laurence Cibrelus</i> , <i>WHO HQ</i>
10:40-10:50	Revised prioritization of risk by country: rationale and impact on preventive approaches, <i>Olivier Ronveaux</i> , <i>WHO HQ</i>
10:50-11:00	Vaccine supply and demand outlook, and market dynamics, <i>Michael Clark</i> , <i>Gavi & Alejandro Costa</i> , <i>WHO HQ</i>
11:00-11:45	Discussion
11:45-11:55	Rapid Containment of outbreaks, Michel Van Herp, MSF
11:55-12:05	Surveillance and laboratory, Mick Mulders, WHO HQ
12:05-12:15	Public Health research and Product development, <i>Matthias Niedrig</i> , <i>Robert Koch Institut</i>
12:15-13:00	Discussion
13:00-14:00	Lunch

Session 4: Group Work - Implementation

14:00-14:05 Introduction to group work

14:05-15:30 Four working groups

- Working Group 1: Improving routine immunization (Salle B)
 - o Chair: Richard Mihigo, WHO AFRO/EPI
- Working Group 2: Preventive campaigns (Salle C)
 - o Chair: Yodit Shalemariam, UNICEF
- Working Group 3: Vaccine market (Room X.7)
 - o Chair: Gavi
- Working Group 4: EYE governance (Room M.205)
 - o Chair: Helen Rees, RITAG

15:30-16:00 Coffee break (Salle B)

Session 5: Wrap-up

Chair: Oyewale Tomori

16:00-17:00	Feedback from	working	group	sessions

17:00-17:30 **Next steps (WHO)**

17:30-19:00 Cocktail (Main Cafeteria)

Working group sessions

Objectives

- Discuss key aspects related to the long-term EYE strategy for yellow fever control
- Get partners input
- Inform the envisioned strategy based on partners input

Methods

- 1h30 guided discussion addressing specific questions;
- Plenary debriefing on discussions outcomes and recommendations

Working group 1: Improving routine immunization

- Recognizing the current challenges in maintaining high routine vaccine coverage levels for YF, which innovative approaches could be proposed during EYE?
- How advocate for routine introduction for the 5 countries where YF vaccine is recommended in routine and not introduced

Working group 2: Mass preventive campaigns

- How to address current challenges in the implementation of a high quality preventive campaign
 - o Includes community engagement
- As EYE rolls out, how do we re-prioritize countries for mass preventive campaigns

Working group 3: Vaccine market

- What innovative approaches should be explored to increase vaccine production over the next ten years

Working group 4: EYE governance

- Which mechanism should be implemented for EYE governance and how partners should be engaged?
- What should be the roles of the governance mechanism?